Pharmaron Inc. provides research and development services, including laboratory chemistry, biosciences, and clinical development services.

Pharmaron Inc.

Biotechnology Research

Pharmaron Biologics (UK) Ltd

Pharmaceutical Manufacturing

Pharmaron US Lab Services

Pharmaron Beijing

Pharmaron, Clinical Development

Pharmaron, Radiolabelled Sciences Division

Pharmaron | 38,324 followers on LinkedIn. Premier life science service provider | Pharmaron (Stock Code: 300759.SZ/3759.HK) is a premier service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of research, development and manufacturing service capabilities throughout the entire drug discovery, preclinical and clinical development process across multiple therapeutic modalities, including small molecules, biologics and CGT products. With over 20,000 employees and operations in China, the U.S., and the U.K., Pharmaron has an excellent track record in the delivery of R&amp;D solutions to its partners in North America, Europe, Japan and China.

Amarjit Girn

Senior Radiochemist at Pharmaron Radiolabelled Sciences

John Townsley

Fabio Spreafico

VP, Business Development (Safety Assessment)

Allison Perkins

Pharmaron

Join us on 𝗗𝗲𝗰𝗲𝗺𝗯𝗲𝗿 𝟱𝘁𝗵 𝗮𝘁 𝟴𝗮𝗺 𝗣𝗧 / 𝟭𝟭𝗮𝗺 𝗘𝗧 / 𝟰𝗽𝗺 𝗚𝗠𝗧 for an in-depth exploration of 𝗺𝗮𝗰𝗿𝗼𝗰𝘆𝗰𝗹𝗲𝘀 in drug design and discovery! In this webinar, Mike Waring , Professor and Head of Medicinal Chemistry at Newcastle University, and Sebastien Campos , Senior Director of Medicinal Chemistry at Pharmaron, will explore how macrocycles are transforming the field. Discover key principles for rational macrocycle design and learn about the unique benefits and challenges of this compound class. Don’t miss the opportunity to gain insights from leading experts in the field—reserve your spot today! 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗵𝗲𝗿𝗲: https://lnkd.in/dDDxTFic #Pharmaron #Webinar #Macrocycles #DrugDesign #DrugDiscovery

Today is World Diabetes Day—a reminder of the urgent need for continued research to address the rising global impact of diabetes. With over 537 million adults affected worldwide, diabetes requires innovative approaches to improve both prevention and treatment. Pharmaron is committed to supporting research that advances understanding and drives new possibilities in diabetes care. We collaborate with scientists and pharmaceutical innovators through strategic partnerships to accelerate diabetes research and foster solutions that can make a lasting difference for patients. Learn more about our commitment to health innovation: https://lnkd.in/dvCVPZ9V #WorldDiabetesDay #DiabetesResearch #Pharmaron #HealthInnovation #LifeSciences

The next CGT webinar is fast approaching! Join us in less than a week to learn more about Pharmaron’s AAV Production Platform. We’ll explore how our advanced strategies can facilitate the AAV product development process leading to BLA/MAA submission. Our agenda features: > Overview of AAV as a therapeutic agent > Key considerations for optimizing the platform > Effective strategies to overcome production challenges Date: November 19, 2024 Time: 8am PST / 11am EST / 4pm GMT Register: https://lnkd.in/dyiasHNG #BiologicsDevelopment #Pharmaron #Webinar #LifeSciences

On World Kindness Day, we celebrate kindness's profound impact across all aspects of life—including science and healthcare. Acts of kindness fuel collaboration, inspire trust and ultimately drive the innovations that improve patient care worldwide. At Pharmaron, kindness is at the heart of our partnerships. By working with integrity and empathy, we aim to create a supportive environment where scientists, researchers, and innovators can thrive together toward better health solutions for all. Let’s make kindness our guiding principle every day. Learn more about our commitment to collaborative success: https://lnkd.in/dvCVPZ9V #WorldKindnessDay #KindnessInScience #Pharmaron #LifeSciences #HealthInnovation

Check out this webinar, which is happening tomorrow in the Bioanalysis Zone. Pharmaron is proud to support this webinar on "The origin-adjusted approach for biomarker quantification by LC–MS". Learn how this approach can enhance your biomarker workflows. https://lnkd.in/d28Jpfrq

Discover when infusion is the best option for drug dosing in animal studies. To learn more, download our flyer here: https://lnkd.in/dGZD6FvN #Pharmacokinetics #DrugDelivery #DrugDiscovery #DrugDevelopment #Pharmaron

Join us at the 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗕𝗶𝗼𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗙𝗼𝗿𝘂𝗺 on 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟮𝟬-𝟮𝟮, 𝟮𝟬𝟮𝟰, where our Analytical Services Manager, Neil Adcock , will present a poster on "Development of an LC/MS/MS method for determination of 4-beta-hydroxycholesterol in Human Plasma". If you are not able to attend, schedule a time to discuss your upcoming projects with our local team by clicking here: https://lnkd.in/dXXaGRif #Pharmaron #EBF #Poster #Bioanalysis

Pharmaron is excited to be a Gold Sponsor at 𝐁𝐎𝐒 𝐌𝐚𝐧𝐜𝐡𝐞𝐬𝐭𝐞𝐫 𝐨𝐧 𝐍𝐨𝐯𝐞𝐦𝐛𝐞𝐫 𝟐𝟔-𝟐𝟕! Join us at 𝐁𝐨𝐨𝐭𝐡 #𝟏𝟏 to meet our team and discover how our fully integrated drug substance and drug product solutions position Pharmaron as a 𝐥𝐞𝐚𝐝𝐢𝐧𝐠 𝐠𝐥𝐨𝐛𝐚𝐥 𝐂𝐃𝐌𝐎 𝐩𝐚𝐫𝐭𝐧𝐞𝐫. Don’t miss the chance to connect - request a meeting with us today: https://lnkd.in/d2U6tbAE #Pharmaron #BOSManchester #CDMO #LifeSciences #DrugDevelopment #Innovation Javier Ruiz Sanz Natalie Windle Paul Quigley Nicolas Duchemin Kassim Kolia

Join us at the 𝗜𝗜𝗦 𝗨𝗞 𝟯𝟬𝘁𝗵 𝗔𝗻𝗻𝘂𝗮𝗹 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 on 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟭𝟱, 𝟮𝟬𝟮𝟰! Our Tritium Deputy Team Leader, Siôn Edwards , will be presenting on “Tritium Labelling of Oligonucleotides” at 9:55 am at The Møller Institute, Cambridge. Don’t miss this opportunity to gain insights into cutting-edge advancements in tritium labelling! #Pharmaron #IIS #Tritium #Oligonucleotides #LifeSciences

November is Alzheimer’s Disease Awareness Month—a time to acknowledge the profound impact this disease has on over 50 million individuals and their families globally. At Pharmaron, we are committed to advancing research that addresses the complexities of Alzheimer’s, from preclinical development to clinical trials, and helping pave the way for more effective treatment options. By partnering with pharmaceutical innovators, we support and accelerate crucial research efforts that could one day transform the future of Alzheimer’s care, offering hope to patients, families, and caregivers worldwide. Learn more about our work in neuroscience research: https://lnkd.in/dvCVPZ9V #AlzheimersAwarenessMonth #Pharmaron #Neuroscience #AlzheimersResearch #HealthInnovation #LifeSciences

Metric
Company Name	Pharmaron Inc.
Symbol
MSH ID	CN:PHARMARON
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	CN
Stage	Post-IPO Equity
Employee Count
Website	pharmaron.cn
LinkedIn	pharmaron
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	19.44K
Web Traffic Growth	-0.79
Valuation
Raised Capital	587.82M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

PHAR

CN:PHARMARON

Pharmaron Inc.

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue